Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the effectiveness and quality of life outcomes of neoadjuvant endocrine therapy compared to chemotherapy in participants with early or locally advanced hormone receptor-positive, HER2-negative breast cancer who have no detectable circulating tumor DNA ctDNA in their blood. This study focuses on determining if endocrine therapy is at least equivalent to chemotherapy for those who respond to initial aromatase inhibitor treatment, using the modified preoperative endocrine prognostic index PEPI score as the main measure. Participants initially provide blood and tumor samples for ctDNA testing using the SignateraTM test. They then take aromatase inhibitor therapy for 4 weeks during a Run-in Phase, with a tumor biopsy after 3 weeks to assess Ki-67 levels. Based on ctDNA results and Ki-67 values, participants are assigned to one of three groups neoadjuvant aromatase inhibitor or tamoxifen treatment, neoadjuvant chemotherapy for endocrine responders, or chemotherapy for non-responders. Treatment lasts 6 to 8 months depending on the group. During the study, participants visit the clinic several times, including before starting treatment, after 3 weeks of endocrine therapy, before beginning the main treatment, mid-therapy, after treatment completion, for surgery and post-surgery checkups, and annually for 5 years after surgery. They provide blood samples for ongoing ctDNA assessment and complete questionnaires on quality of life, symptoms, and sexual health. The study tracks outcomes like PEPI score at surgery and long-term survival and disease-free survival over 5 years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Researchers are evaluating how receiving an mRNA COVID-19 vaccine within 3 months before starting immune checkpoint inhibitor ICI therapy affects treatment response in patients with hepatocellular carcinoma HCC, an advanced liver cancer. This retrospective cohort study aims to understand if vaccination improves overall response to ICIs and explores related outcomes like survival and safety. The study is conducted across multiple centers in Austria where COVID-19 vaccination programs have been widely implemented. Participants include patients with confirmed HCC undergoing ICI therapy, divided into those vaccinated with an mRNA COVID-19 vaccine within 100 days before treatment and those not vaccinated in that timeframe. The study compares these groups to assess responses using imaging criteria and clinical data. Secondary aims evaluate survival times, progression rates, and safety outcomes such as immune-related adverse events and treatment discontinuations. During the study, researchers review existing electronic medical records, imaging response assessments, and clinical data for up to four years. They measure the best overall response using mRECIST criteria as the primary outcome and also track overall survival, progression-free survival, and time to progression. Safety data, including steroid use and toxicity leading to treatment stop, are also analyzed. The study does not involve active treatment administration but observes outcomes retrospectively.